This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Barton, D. P. J. Articles by Djeu, J. Y. Search for Related Content PubMed PubMed Citation Articles by Barton, D. P. J. Articles by Blanchard, D. K. Articles by Duan, C. Articles by Roberts, W. S. Articles by Cavanagh, D. Articles by DeCesare, S. Articles by Djeu, J. Y. Social Bookmarking                   What's this?

Interleukin-12 Synergizes With Interleukin-2 to Generate Lymphokine-Activated Killer Activity in Peripheral Blood Mononuclear Cells Cultured in Ovarian Cancer Ascitic Fluid

D. Kay Blanchard, PhD

Chunni Duan, MSc

William S. Roberts, MD

Denis Cavanagh, MD

Steven DeCesare, MD

Julie Y. Djeu, PhD

Immunology Program, Division of Gynecologic Oncology, H. Lee Moffitt Cancer Center and Research Institute. University of South Florida College of Medicine, Tampa, Florida

Objective: The ascites-associated lymphocytes in ovarian cancer have altered immunologic function, and cell-free ascitic fluid has immunomodulating properties. We determined (1) whether interleukin (IL)-2 could induce lymphokine-activated killer (LAK) activity in normal peripheral blood mononuclear cells (PBMC) cultured in ovarian cancer ascitic fluid, and (2) whether IL-12 could synergize with IL-2 to generate LAK activity in normal PBMC cultured in ascitic fluid.

Methods: Normal PBMC were cultured in control medium and in media consisting of 50% ascitic fluid (ascitic medium), with and without IL-2 and LI-12. Cell activation to assess LAK activity (cell lysis) was determined in a ⁵¹Cr-release assay with the tumor cell lines FMEX and SKoV3 as target cells. To determine a possible mechanism for any synergistic effect, the expression of perforin, a pore-forming protein, was determined by Northern blot analysis.

Results: Interleukin-2 alone could not induce LAK activity in normal PBMC cultured in 50% ascitic fluid for up to 3 days. Interleukin-12 did mediate some or minimal LAK activity after 1, 2, or 3 days of incubation in control medium or in 50% ascitic fluid. When IL-2 and IL-12 were used in combination, PBMC cultured for 3 days in 50% ascitic fluid had remarkably high lytic activity against FMEX and SKOV3 tumor cells. In some experiments, this cytotoxicity was greater than that in PBMC cultured in control medium with IL-2 and IL-12. Lower concentrations of IL-12 (1 U/mL) with IL-2 (100 U/mL) were as effective as, and often more effective than, higher doses of IL-12 with IL-2. Very low-dose IL-12 (0.01-0.03 U/mL) in combination with IL-2 also induced a range of cytotoxicities. Only the combination of IL-2 and IL-12 up-regulated expression of perforin mRNA in ascitic medium.

Conclusions: The cytotoxicity responses of PBMC cultured in ascitic fluid in the presence of IL-2 and IL-12 are complex. Low-dose IL-2 and IL-12 can overcome the inhibitory property of ascitic fluid on LAK generration and can restore and enhance cytotoxic activity, possibly by reconstituting the expression of perforin. These findings may have therapeutic potential.

Key Words: Interleukin-2 • interleukin-12 • ovarian cancer ascites • lymphokine-activated killer activity

Journal of the Society for Gynecologic Investigation, Vol. 2, No. 6, 762-771 (1995)
DOI: 10.1177/107155769500200607


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?